Salvador Arlandis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Salvador Arlandis has a total of 246 co-authors. Here are the top co-authors by number of shared publications:
- Esther Martínez-Cuenca
Urology Department Hospital Universitari I Politècnic La Fe València Spain
7 shared publications - Luis López-Fando Lavalle
Department of Urology, Hospital Universitario de La Princesa, 28006 Madrid, Spain
7 shared publications - Paul Abrams
Bristol Urological Institute, Southmead Hospital Bristol UK
6 shared publications - Carlos Errando Smet
Functional Urology and Urodynamics Department, Fundació Puigvert, Barcelona, Spain
4 shared publications - Carlos Muller Arteaga
Urology Department, Complexo Hospitalario Universitario de Vigo (CHUVI), 36312 Vigo, Spain
4 shared publications - David Castro-Diaz
Department of Urology, Hospital Universitario de Canarias, San Cristóbal de La Laguna, Spain
4 shared publications
Latest Publications
- 14 September 2026
- Published by Wiley in Neurourology and Urodynamics
Randomized Trial of Percutaneous Versus Transcutaneous Tibial Nerve Stimulation in The Treatment of Refractory Overactive Bladder: Results From The TRANSPER Trial
Background: Overactive bladder (OAB) affects ~21% of the Spanish population. In patients, refractory to pharmacological therapy, tibial nerve stimulation—percutaneous (PTNS) or transcutaneous (TTNS)—is an established treatment option. As maintenance therapy is often required, home‐based TTNS could reduce the healthcare burden. We compared the clinical efficacy of TTNS and PTNS in refractory OAB. Methods: We conducted a prospective, randomized, double‐blind, single‐center, parallel‐arm clinical trial (IRB 2022‐598‐1). Adults with pharmacologically refractory OAB were randomized to PTNS or TTNS using sealed envelopes; patients and evaluators were blinded to allocation. Stimulation was delivered at 200 μs pulse duration and 20 Hz frequency, with adjustable amplitude (0–10 mA). Treatment consisted of twelve weekly 30 min sessions. Primary outcomes were changes in OABq‐SF symptom severity and quality‐of‐life (QoL) scores from baseline to 1 week after treatment, and Treatment Benefit Scale (TBS) responses. Secondary outcomes included bladder diary parameters. Statistical analyses included the chi‐square, Wilcoxon, and Mann‐Whitney U tests. Results: Fifty patients were enrolled (TTNS, n = 23; PTNS, n = 27). Mean age was 56 years (SD 15.4), and 78% were women. Baseline characteristics were comparable. Both groups showed significant improvements in OABq‐SF symptom (TTNS − 10.7, p = 0.001; PTNS − 11.7, p = 0.001) and QoL scores (TTNS + 11.5, p = 0.011; PTNS + 11.8, p = 0.003), with no significant between‐group differences. Treatment satisfaction was similar (TTNS 69.6% vs. PTNS 63%). Bladder diary parameters improved in both groups. The main limitation was the modest sample size. Conclusions: TTNS was non‐inferior to PTNS for the primary outcomes in patients with refractory OAB. TTNS may be a feasible home‐based alternative, potentially reducing outpatient resource utilization. This clinical trial is registered in ClinicalTrial.gov , NCT ID not yet assigned.
- 14 September 2026
- Published by Wiley in Neurourology and Urodynamics
Randomized Trial of Percutaneous Versus Transcutaneous Tibial Nerve Stimulation in The Treatment of Refractory Overactive Bladder: Results From The TRANSPER Trial
Background: Overactive bladder (OAB) affects ~21% of the Spanish population. In patients, refractory to pharmacological therapy, tibial nerve stimulation—percutaneous (PTNS) or transcutaneous (TTNS)—is an established treatment option. As maintenance therapy is often required, home‐based TTNS could reduce the healthcare burden. We compared the clinical efficacy of TTNS and PTNS in refractory OAB. Methods: We conducted a prospective, randomized, double‐blind, single‐center, parallel‐arm clinical trial (IRB 2022‐598‐1). Adults with pharmacologically refractory OAB were randomized to PTNS or TTNS using sealed envelopes; patients and evaluators were blinded to allocation. Stimulation was delivered at 200 μs pulse duration and 20 Hz frequency, with adjustable amplitude (0–10 mA). Treatment consisted of twelve weekly 30 min sessions. Primary outcomes were changes in OABq‐SF symptom severity and quality‐of‐life (QoL) scores from baseline to 1 week after treatment, and Treatment Benefit Scale (TBS) responses. Secondary outcomes included bladder diary parameters. Statistical analyses included the chi‐square, Wilcoxon, and Mann‐Whitney U tests. Results: Fifty patients were enrolled (TTNS, n = 23; PTNS, n = 27). Mean age was 56 years (SD 15.4), and 78% were women. Baseline characteristics were comparable. Both groups showed significant improvements in OABq‐SF symptom (TTNS − 10.7, p = 0.001; PTNS − 11.7, p = 0.001) and QoL scores (TTNS + 11.5, p = 0.011; PTNS + 11.8, p = 0.003), with no significant between‐group differences. Treatment satisfaction was similar (TTNS 69.6% vs. PTNS 63%). Bladder diary parameters improved in both groups. The main limitation was the modest sample size. Conclusions: TTNS was non‐inferior to PTNS for the primary outcomes in patients with refractory OAB. TTNS may be a feasible home‐based alternative, potentially reducing outpatient resource utilization. This clinical trial is registered in ClinicalTrial.gov , NCT ID not yet assigned.
- Open Access
- 30 March 2026
- Published by Elsevier in Continence
- Vol. 18
Position of the Ibero-American Society of Neurourology and Urogynecology (SINUG) on the treatment of musculoskeletal phenotype in chronic pelvic pain syndrome
- 30 March 2026
- Published by Elsevier in Continence
- Vol. 18
Open AccessPosition of the Ibero-American Society of Neurourology and Urogynecology (SINUG) on the treatment of musculoskeletal phenotype in chronic pelvic pain syndrome
- 6 May 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (2) , 211-214
Management of Stress Urinary Incontinence in Patients with Underactive Bladder
- 6 May 2025
- Published by Elsevier in European Urology Focus
- Vol. 11 (2) , 211-214
Management of Stress Urinary Incontinence in Patients with Underactive Bladder
- Open Access
- 11 April 2025
- Published by MDPI AG in Complications
- Vol. 2 (2) , 11
Management of Complications in Laparoscopic Sacrocolpopexy: Focus on Urinary Incontinence
Pelvic organ prolapse (POP) is a prevalent condition worldwide with detrimental effects on patients’ quality of life. Laparoscopic sacrocolpopexy (LSC) has emerged as the gold standard for managing complex and high-grade POP. While anatomical and subjective outcomes have been extensively documented, the management of its associated complications, particularly urinary incontinence, remains challenging. This study evaluates the strategies implemented to address complications arising from LSC, focusing on urinary incontinence. A retrospective multicenter study analyzed 325 patients who underwent LSC using lightweight macroporous Surelift Uplift mesh between 2011 and 2019. Data on perioperative and long-term complications, with emphasis on urinary incontinence management, were extracted from participating centers. Among them, the incidence of new-onset stress urinary incontinence (SUI) postoperatively was 12.9%. A total of 21 patients required further treatment for urinary symptoms, including mid-urethral sling (MUS) procedures in 5.5% and botulinum toxin injections for overactive bladder (OAB) in 0.9%. The findings underscore the importance of proactive and tailored management strategies for urinary incontinence following LSC. While the procedure demonstrates low complication rates and high anatomical success, urinary symptoms require vigilant monitoring and intervention in a two-step procedure for stress incontinence, if needed.
- 11 April 2025
- Published by MDPI AG in Complications
- Vol. 2 (2) , 11
Open AccessManagement of Complications in Laparoscopic Sacrocolpopexy: Focus on Urinary Incontinence
Pelvic organ prolapse (POP) is a prevalent condition worldwide with detrimental effects on patients’ quality of life. Laparoscopic sacrocolpopexy (LSC) has emerged as the gold standard for managing complex and high-grade POP. While anatomical and subjective outcomes have been extensively documented, the management of its associated complications, particularly urinary incontinence, remains challenging. This study evaluates the strategies implemented to address complications arising from LSC, focusing on urinary incontinence. A retrospective multicenter study analyzed 325 patients who underwent LSC using lightweight macroporous Surelift Uplift mesh between 2011 and 2019. Data on perioperative and long-term complications, with emphasis on urinary incontinence management, were extracted from participating centers. Among them, the incidence of new-onset stress urinary incontinence (SUI) postoperatively was 12.9%. A total of 21 patients required further treatment for urinary symptoms, including mid-urethral sling (MUS) procedures in 5.5% and botulinum toxin injections for overactive bladder (OAB) in 0.9%. The findings underscore the importance of proactive and tailored management strategies for urinary incontinence following LSC. While the procedure demonstrates low complication rates and high anatomical success, urinary symptoms require vigilant monitoring and intervention in a two-step procedure for stress incontinence, if needed.
- Open Access
- 10 March 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 609-615
Can We Improve Our Routine Urological Assessment to Exclude Neurogenic Causes for Lower Urinary Tract Dysfunction? ICI‐RS 2024
Aims: After presentation with urinary symptoms, an underlying neurological mechanism sometimes emerges subsequently. Increased awareness may bring earlier diagnosis, improving prognosis and outcomes.Methods: A 2024 International Consultation on Incontinence Research Society think‐tank considered the clinical pathway for identification of an undiagnosed neurological or autonomic contribution precipitating urinary symptoms, and the implications for prognosis.Results: Alongside adult‐onset neurogenic conditions, potential for missed diagnosis includes congenital and pediatric‐acquired neurogenic conditions, which may become symptomatic during a growth spurt due to spinal cord tethering. Detailed assessment is needed, also considering bowel and sexual dysfunction, with timely referral to neurology to reduce preventable progression of disease. In neurological assessment, control of micturition is often poorly characterized compared with other aspects of spinal cord function and the cranial nerves. Screening tools may be used to identify people who have increased likelihood of particular conditions, but currently available tools are either single‐system or population specific. In addition to the general pelvic examination, the assessment of sacral reflexes and pelvic sensations can suggest a neurological mechanism, though the sensitivity and specificity of the neuro‐urological examination is unknown. Including the results of the neuro‐perineal examination in the urodynamic report may improve the interpretation of the results and potentially support a neurological aetiology.Conclusion: Future research should consider the value of neuro‐urological examination in diagnosis of occult neurological disease, the development of an occult neurology screening tool/risk scoring based on pelvic organ symptoms, and appropriateness of non‐neurologist practitioners requesting neurological investigations such as MRI scanning.Clinical Trial Registration: Does not apply.
- 10 March 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 609-615
Open AccessCan We Improve Our Routine Urological Assessment to Exclude Neurogenic Causes for Lower Urinary Tract Dysfunction? ICI‐RS 2024
Aims: After presentation with urinary symptoms, an underlying neurological mechanism sometimes emerges subsequently. Increased awareness may bring earlier diagnosis, improving prognosis and outcomes.Methods: A 2024 International Consultation on Incontinence Research Society think‐tank considered the clinical pathway for identification of an undiagnosed neurological or autonomic contribution precipitating urinary symptoms, and the implications for prognosis.Results: Alongside adult‐onset neurogenic conditions, potential for missed diagnosis includes congenital and pediatric‐acquired neurogenic conditions, which may become symptomatic during a growth spurt due to spinal cord tethering. Detailed assessment is needed, also considering bowel and sexual dysfunction, with timely referral to neurology to reduce preventable progression of disease. In neurological assessment, control of micturition is often poorly characterized compared with other aspects of spinal cord function and the cranial nerves. Screening tools may be used to identify people who have increased likelihood of particular conditions, but currently available tools are either single‐system or population specific. In addition to the general pelvic examination, the assessment of sacral reflexes and pelvic sensations can suggest a neurological mechanism, though the sensitivity and specificity of the neuro‐urological examination is unknown. Including the results of the neuro‐perineal examination in the urodynamic report may improve the interpretation of the results and potentially support a neurological aetiology.Conclusion: Future research should consider the value of neuro‐urological examination in diagnosis of occult neurological disease, the development of an occult neurology screening tool/risk scoring based on pelvic organ symptoms, and appropriateness of non‐neurologist practitioners requesting neurological investigations such as MRI scanning.Clinical Trial Registration: Does not apply.
- Open Access
- 13 January 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 644-650
Do We Have Sufficient Evidence to Derive Innovative Approaches to Assessing Unmet Need, Delivering Education on Bladder and Bowel Continence Health, and Providing a Better Environment for Joint Decision‐Making? ICI‐RS 2024
Context: Improved continence outcomes are reliant on identification of unmet need, education delivery, and shared decision‐making. The evidence base on which to derive innovative approaches in these areas was unclear.Methods: A debate held at the International Consultation on Incontinence‐Research Society meeting, held in Bristol in June 2024, considered ways to improve research requirements to advance these areas.Results and Conclusion: Artificial intelligence solutions and digital approaches to healthcare are emerging at pace and offer possibilities to improve these three key areas but this must be driven by person‐centered approaches. Care must be taken to avoid increasing inequality through digital exclusion and language barriers. Research questions are highlighted to derive innovation in these three key areas.
- 13 January 2025
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 644-650
Open AccessDo We Have Sufficient Evidence to Derive Innovative Approaches to Assessing Unmet Need, Delivering Education on Bladder and Bowel Continence Health, and Providing a Better Environment for Joint Decision‐Making? ICI‐RS 2024
Context: Improved continence outcomes are reliant on identification of unmet need, education delivery, and shared decision‐making. The evidence base on which to derive innovative approaches in these areas was unclear.Methods: A debate held at the International Consultation on Incontinence‐Research Society meeting, held in Bristol in June 2024, considered ways to improve research requirements to advance these areas.Results and Conclusion: Artificial intelligence solutions and digital approaches to healthcare are emerging at pace and offer possibilities to improve these three key areas but this must be driven by person‐centered approaches. Care must be taken to avoid increasing inequality through digital exclusion and language barriers. Research questions are highlighted to derive innovation in these three key areas.
- 27 December 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 601-608
Moving Beyond the Bladder Diary: Does New Technology Now Allow Us to Take Investigation of LUTS Into the Community? ICI‐RS 2024
Context: Lower Urinary Tract Symptoms (LUTS) are defined by their distressing effect on patients' day‐to‐day life. Given the pressures on secondary care resources, LUTS may be overlooked or inadequately assessed and therefore patients may be burdened for an extended period before treatment.Methods: In a debate held at the International Consultation on Incontinence Research Society (ICI‐RS) meeting in Bristol in June 2024, we considered how new technologies might contribute to an expedited, dignified and effective investigation of LUTS.Results: We describe three broad areas where technology has a role to play: streamlining of existing investigations through mobile and miniaturized technology; entirely new investigations made possible by the technology; and advanced analytics to provide better insights from the data available.Conclusion: We describe key research questions that will signpost us toward answering the question raised in the title.
- 27 December 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 601-608
Moving Beyond the Bladder Diary: Does New Technology Now Allow Us to Take Investigation of LUTS Into the Community? ICI‐RS 2024
Context: Lower Urinary Tract Symptoms (LUTS) are defined by their distressing effect on patients' day‐to‐day life. Given the pressures on secondary care resources, LUTS may be overlooked or inadequately assessed and therefore patients may be burdened for an extended period before treatment.Methods: In a debate held at the International Consultation on Incontinence Research Society (ICI‐RS) meeting in Bristol in June 2024, we considered how new technologies might contribute to an expedited, dignified and effective investigation of LUTS.Results: We describe three broad areas where technology has a role to play: streamlining of existing investigations through mobile and miniaturized technology; entirely new investigations made possible by the technology; and advanced analytics to provide better insights from the data available.Conclusion: We describe key research questions that will signpost us toward answering the question raised in the title.
- 30 October 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 539-547
Think Tank 2: How Do We Precisely Define the “High Risk Bladder” and What Are the Interrelationships Between Inflammation, Blood Flow, Fibrosis, and Loss of Bladder Compliance?
Introduction: Defining “high‐risk bladder” or “high‐pressure bladder” involves recognizing the potential for an unsafe lower urinary tract, where dysfunction in storage and micturition can threaten upper urinary tract health, leading to unfavorable outcomes like dialysis, recurrent infections, systemic impact, or mortality.Methods: ICI‐RS was held in Bristol in June 2024, and Think Tank 2 aimed to define research priorities including identifying clinical predictors and developing prevention and monitoring strategies.Results: Risk factors encompass both congenital and neurogenic lower urinary tract dysfunction, bladder outlet obstruction, vascular diseases, and inflammatory disorders, but a validated stratification risk is lacking. Reduced compliance and detrusor overactivity lead to high filling pressures and raised detrusor leak point pressure, playing urodynamic studies a crucial role in risk assessment, though further research is needed for different neurogenic populations. Congenital conditions such as spina bifida, posterior urethral valves, and bladder exstrophy also contribute to a high‐risk bladder through fibrosis and reduced compliance. Inflammation and ischemia are key factors, with inflammation leading to fibrosis and impaired bladder storage and voiding function. Novel treatments, including sGC activators, PDE5 inhibitors, and regenerative therapies like stem cell injections and extracorporeal shock wave treatment, show promise in mitigating fibrosis and improving bladder compliance.Conclusions: Identifying and validating clinical risk stratification models, precise biomarkers and therapeutic windows remains essential for effective management and reversal of bladder fibrosis and dysfunction.
- 30 October 2024
- Published by Wiley in Neurourology and Urodynamics
- Vol. 44 (3) , 539-547
Think Tank 2: How Do We Precisely Define the “High Risk Bladder” and What Are the Interrelationships Between Inflammation, Blood Flow, Fibrosis, and Loss of Bladder Compliance?
Introduction: Defining “high‐risk bladder” or “high‐pressure bladder” involves recognizing the potential for an unsafe lower urinary tract, where dysfunction in storage and micturition can threaten upper urinary tract health, leading to unfavorable outcomes like dialysis, recurrent infections, systemic impact, or mortality.Methods: ICI‐RS was held in Bristol in June 2024, and Think Tank 2 aimed to define research priorities including identifying clinical predictors and developing prevention and monitoring strategies.Results: Risk factors encompass both congenital and neurogenic lower urinary tract dysfunction, bladder outlet obstruction, vascular diseases, and inflammatory disorders, but a validated stratification risk is lacking. Reduced compliance and detrusor overactivity lead to high filling pressures and raised detrusor leak point pressure, playing urodynamic studies a crucial role in risk assessment, though further research is needed for different neurogenic populations. Congenital conditions such as spina bifida, posterior urethral valves, and bladder exstrophy also contribute to a high‐risk bladder through fibrosis and reduced compliance. Inflammation and ischemia are key factors, with inflammation leading to fibrosis and impaired bladder storage and voiding function. Novel treatments, including sGC activators, PDE5 inhibitors, and regenerative therapies like stem cell injections and extracorporeal shock wave treatment, show promise in mitigating fibrosis and improving bladder compliance.Conclusions: Identifying and validating clinical risk stratification models, precise biomarkers and therapeutic windows remains essential for effective management and reversal of bladder fibrosis and dysfunction.
- Open Access
- 10 October 2024
- Published by Elsevier in Continence
- Vol. 12
Position of the Ibero-American Society of Neurourology and Urogynecology (SINUG) on the urodynamics (UDS) in women undergoing surgical treatment for stress urinary incontinence (SUI)
- 10 October 2024
- Published by Elsevier in Continence
- Vol. 12
Open AccessPosition of the Ibero-American Society of Neurourology and Urogynecology (SINUG) on the urodynamics (UDS) in women undergoing surgical treatment for stress urinary incontinence (SUI)